Home > List All Publishers > La Merie Publishing

La Merie Publishing

La Merie Business Intelligence is focused on Research and Development in the Biopharmaceutical Industry. La Merie provides information about biopharmaceutical R&D and competitive intelligence by Publishing, Consultancy and its Biotech Portal PipelineReview.com. The information is retrieved from La Merie’s in house R&D database, news portal and direct as well as desktop searches. La Merie has a focus on Biologics, including antibodies, proteins, peptides, vaccines, RNA, DNA and cell therapy.

La Merie publishes Competitor Analysis Reports, Brief Reports and Full Reports. The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies.

The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as a la carte or obtained by subscribing to R&D Pipeline News. R&D Pipeline News is published weekly 50-times a year and each issue contains competitor evaluations. Individual products from the Competitor Analysis Series and R&D Pipeline News are elaborated by independent analysts of La Merie Business Intelligence. Brief Reports on Target Pipelines include assessment of the scientific as well as business perspective of new targets. Full reports provide in-depth analysis of product portfolios, R&D pipelines, competitive environment and a critical assessment of the pipeline perspective.

List of reports from La Merie Publishing

Competitor Analysis: Phosphodiesterase-4 (PDE-4) Inhibitors 1/1/2010 \| published by: La Merie Publishing ... includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project ... \| read more...	$287.00
Competitor Analysis: Growth Factors for Bone, Dental, Cartilage and Tendon Repair 12/1/2009 \| published by: La Merie Publishing ... bone, dental, cartilage and soft tissue such as tendons as of December 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the ... \| read more...	$450.00
Competitor Analysis Neurotrophic Growth Factors 12/1/2009 \| published by: La Merie Publishing ... nervous system tissue as of December 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the ... \| read more...	$603.00
Competitor Analysis: Tissue Growth Factors 12/1/2009 \| published by: La Merie Publishing ... as of December 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be ... \| read more...	$1,180.00
Competitor Analysis: FGF-R Agonists and Antagonists 11/1/2009 \| published by: La Merie Publishing ... or treatment of cancer as of November 2009. The family of fibroblast growth factors (FGFs) regulates a plethora of developmental processes, including brain patterning, branching morphogenesis and limb development. The fibroblast growth factor receptors consist ... \| read more...	$445.00
Competitor Analysis: CXCR and CXCL Agonists and Antagonists 11/1/2009 \| published by: La Merie Publishing ... and inflammatory diseases of lung, skin or colon as of November 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication ... \| read more...	$445.00
Competitor Analysis: TGF-R Agonists and Antagonists 11/1/2009 \| published by: La Merie Publishing ... fibrotic diseases of lung, skin or kidney as of November 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. ... \| read more...	$297.00
Competitor Analysis: FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART) 11/1/2009 \| published by: La Merie Publishing ... and LH receptor agonists for treatment of infertility. Follicle-stimulating hormone (FSH) now has become an established means of ovulation induction (OI) as part of assisted reproductive technology (ART). FSH is used to induce development of ... \| read more...	$297.00
Competitor Analysis: Thrombopoiesis-Stimulating Agents (TPO) 11/1/2009 \| published by: La Merie Publishing ... and R&D pipeline includes six products on the market, further eight clinical stage and further ten preclinical new molecules in various indications from the product categories antibody, protein, peptide and small molecule (NCE). Thrombopoiesis stimulating ... \| read more...	$223.00
Competitor Analysis: Proteasome Inhibitors 11/1/2009 \| published by: La Merie Publishing ... downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work ... \| read more...	$150.00
Competitor Analysis: PDGF-R Agonists and Antagonists 10/1/2009 \| published by: La Merie Publishing ... of cancer as of October 2009. Growth factors are extracellular signaling polypeptides regulating cell proliferation, differentiation and survival. They exert a wide spectrum of biological activities selectively binding to and activating specific membrane receptors which ... \| read more...	$1,269.00
Competitor Analysis: VEGF and VEGF-R Agonists and Antagonists 9/1/2009 \| published by: La Merie Publishing ... of September 2009. The importance of tumor angiogenesis in tumor biology is now widely accepted and has emerged as a valid therapeutic target in oncology. Vascular endothelial growth factor (VEGF) represents a key mediator of ... \| read more...	$2,538.00
Competitor Analysis: CHK and KSP/Eg5 Inhibitors 8/1/2009 \| published by: La Merie Publishing ... cancer as of August 2009. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will ... \| read more...	$750.00
Coagulation Factors 2009: Target Pipeline and Corporate Benchmark Analysis 8/1/2009 \| published by: La Merie Publishing ... pipeline for each of the coagulation factors used for systemic and topical administration. Companies active in the therapeutic coagulation business are evaluated and the strengths, weaknesses, opportunities and threats (SWOT) in their R&D pipeline benchmarked ... \| read more...	$3,454.00
Competitor Analysis: Immunotoxins 7/1/2009 \| published by: La Merie Publishing ... a promising molecular cancer treatment strategy. Its main advantage is seletive cytotoxicity towards tumor cells and minimal toxicity in normal tissues.The clinical development of immunotoxins in the treatment of solid tumors has been impeded in ... \| read more...	$210.00
Competitor Analysis: PI3K-AKT-mTOR Inhibitors 7/1/2009 \| published by: La Merie Publishing ... for treatment of cancer or inflammatory diseases as of July 2009. The phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling pathway plays a critical role in the regulation of cellular growth, survival, and proliferation. Dysregulation of ... \| read more...	$2,115.00
Competitor Analysis: Bcr-Abl and Src Kinase Inhibitors 7/1/2009 \| published by: La Merie Publishing ... Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia (Ph) chromosome, which results from a reciprocal translocation between the long arms of the chromosomes 9 and 22 t(9;22)(q34;q11). This translocation creates two ... \| read more...	$840.00
Competitor Analysis: Immunocytokines 6/1/2009 \| published by: La Merie Publishing ... Although the human cytokines interleukin-2 (IL-2) and tumor necrosis factor (TNF) alpha are approved marketed for tumor therapy, their use is rather limited due to severe systemic side effects. Targeted delivery of the cytokine may ... \| read more...	$212.66
Competitor Analysis: Aurora Kinase Inhibitors 6/1/2009 \| published by: La Merie Publishing ... tumor growth, is highly regulated to ensure accurate and equal segregation of genetic materials from parent cells to daughter cells. Main effectors of this process are mitotic spindles and centrosomes.157 Disruption of the process results ... \| read more...	$250.00
Competitor Analysis: MEK Inhibitors 6/1/2009 \| published by: La Merie Publishing ... are conserved proteins that regulate cell growth, division and death. Although activated in the cytosol, the MAPKs translocate to the nucleus upon activation and phosphorylate a large number of nuclear proteins. Investigating how Ras transmits ... \| read more...	$210.00
Competitor Analysis: NGF Agonists & Antagonists 5/1/2009 \| published by: La Merie Publishing ... or Alzheimer’s disease and peripheral neuropathies as of May 2009. Nerve growth factor (NGF) is the prototypical member of the family of neurotrophin growth factors that are involved in the growth and survival of nervous ... \| read more...	$140.00
Competitor Analysis: Ras-Raf-MEK-ERK Inhibitors 5/1/2009 \| published by: La Merie Publishing ... kinases (MAPKs) are conserved proteins that regulate cell growth, division and death. Although activated in the cytosol, the MAPKs translocate to the nucleus upon activation and phosphorylate a large number of nuclear proteins. Investigating how ... \| read more...	$500.00
Competitor Analysis: Hypoxia-Inducible Factor (HIF) 4/24/2009 \| published by: La Merie Publishing ... agonists to induce angiogenesis as of April 2009. Hypoxia-inducible factor 1 (HIF-1) is a key regulator of angiogenic and glucose metabolism processes utilised by tumour cells for survival and growth under hypoxic conditions. While HIF-1α ... \| read more...	$140.00
Competitor Analysis: PARP Inhibitors 4/15/2009 \| published by: La Merie Publishing ... (PARPs) are a family of nuclear enzymes implicated in the regulation of multiple physiological cellular functions, including DNA repair, gene transcription, protein modification and cell signaling. Over-activation of PARP results in pathologic alteration of cellular ... \| read more...	$140.00
Competitor Analysis: CEA Antibodies 4/7/2009 \| published by: La Merie Publishing ... includes a compilation of current active projects in research and development of epithelial cell adhesion molecule (EpCAM) targeting antibodies and antibody-based constructs. In addition, the report lists company-specific R&D pipelines of EpCAM Antagonists. Competitor projects ... \| read more...	$70.00

< prev 1 2 3 4 5 6 7 next >